WEREWOLF THERAPEUTICS

Werewolf Therapeutics Reports First Quarter 2025 Financial Results and Provides Business Update

08 5月 2025 07:00:00 条件 Nasdaq GlobeNewswire

Werewolf Therapeutics Presents New Preclinical Data Further Characterizing its IL-10 INDUKINE Molecule, WTX-921, for the Treatment of Inflammatory Bowel Disease (IBD) at AAI Annual Meeting

05 5月 2025 08:05:00 条件 Nasdaq GlobeNewswire

Werewolf Therapeutics to Participate in Upcoming Investor Conferences

05 5月 2025 08:00:00 条件 Nasdaq GlobeNewswire

Werewolf Therapeutics Appoints Steven Bloom as Chief Business Officer

17 4月 2025 08:00:00 条件 Nasdaq GlobeNewswire

Werewolf Therapeutics to Present at the 24th Annual Needham Virtual Healthcare Conference

31 3月 2025 08:00:00 条件 Nasdaq GlobeNewswire

Werewolf Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update

11 3月 2025 07:00:00 条件 Nasdaq GlobeNewswire

Werewolf Therapeutics to Present at the 2025 Leerink Partners Global Biopharma Conference

04 3月 2025 08:00:01 条件 Nasdaq GlobeNewswire

Werewolf Therapeutics Appoints Anil Singhal, Ph.D., to its Board of Directors

24 2月 2025 07:30:00 条件 Nasdaq GlobeNewswire

Werewolf Therapeutics Provides Business Update and Highlights 2025 Strategic Outlook

13 1月 2025 08:00:01 条件 Nasdaq GlobeNewswire

Werewolf Therapeutics to Participate in the 7th Annual Evercore ISI HealthCONx Healthcare Conference

20 11月 2024 08:00:00 条件 Nasdaq GlobeNewswire

Werewolf Therapeutics Presents Preclinical and Clinical Data at the Society for Immunotherapy of Cancer’s (SITC) 39th Annual Meeting

07 11月 2024 09:02:00 条件 Nasdaq GlobeNewswire

Werewolf Therapeutics Reports Third Quarter 2024 Financial Results and Provides Business Update

07 11月 2024 09:00:00 条件 Nasdaq GlobeNewswire

Werewolf Therapeutics Announces Promising New Development Candidate, WTX-921, a first-of-its-kind IL-10 INDUKINE™ Molecule for Inflammatory Diseases

31 10月 2024 08:00:00 条件 Nasdaq GlobeNewswire

Werewolf Therapeutics to Present Posters at the Society for Immunotherapy of Cancer’s (SITC) 39th Annual Meeting

04 10月 2024 09:00:00 条件 Nasdaq GlobeNewswire

Werewolf Therapeutics to Participate in the H.C. Wainwright 26th Annual Global Investment Conference

03 9月 2024 08:00:00 条件 Nasdaq GlobeNewswire

Werewolf Therapeutics Reports Second Quarter 2024 Financial Results and Provides Business Update

08 8月 2024 07:05:00 条件 Nasdaq GlobeNewswire

Werewolf Therapeutics Highlights Initial Safety and Efficacy Data from its Ongoing Phase 1 Clinical Trial Evaluating WTX-330 in Patients with Advanced or Metastatic Solid Tumors or Non-Hodgkin Lymphoma

25 6月 2024 07:00:00 条件 Nasdaq GlobeNewswire

Werewolf Therapeutics to Present Data from Ongoing Phase 1/1b Clinical Trial of WTX-124 as Monotherapy and in Combination with Pembrolizumab in Solid Tumors

01 6月 2024 08:59:59 条件 Nasdaq GlobeNewswire

Werewolf Therapeutics to Participate at the Jefferies Global Healthcare Conference

30 5月 2024 08:00:00 条件 Nasdaq GlobeNewswire

Werewolf Therapeutics to Present Updated Data from Phase 1/1b Clinical Trial of WTX-124 as Monotherapy and in Combination with Pembrolizumab in Solid Tumors at 2024 ASCO Annual Meeting

23 5月 2024 17:00:00 条件 Nasdaq GlobeNewswire